Perivascular cells regulate endothelial membrane type-1 matrix metalloproteinase activity

Biochemical and Biophysical Research Communications

Volumn 282, Issue 2, 2001, Pages 463-473

  Lafleur, Marc A ^a   Forsyth, Peter A ^b   Atkinson, Susan J ^a   Murphy, Gillian ^a   Edwards, Dylan R ^a  

^a UNIVERSITY OF EAST ANGLIA   (United Kingdom)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

Angiogenesis; Endothelial cells; MMPs; MT1 MMP; Pericytes; Smooth muscle cells; TIMPs

Indexed keywords

GELATINASE A; INTERSTITIAL COLLAGENASE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ANGIOGENESIS; ARTICLE; COCULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PERICYTE; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; VASCULAR SMOOTH MUSCLE; WESTERN BLOTTING; ZYMOGRAPHY;

EID: 0034805778     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1006/bbrc.2001.4596     Document Type: Article

References (58)

1. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis
2. Angiogenesis
3. Tumor angiogenesis
4. Isolation and characterization of angiogenin, an angiogenic protein from human carcinoma cells
5. Angiostatin: A novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma
6. Matrix metallopreteinase-9 triggers the angiogenic switch during carcinogenesis
7. Migration and proliferation of endothelial cells in preformed and newly formed blood vessels during angiogenesis
8. Matrix metalloproteinases and the development of cancer
9. Relating matrix metalloproteinase structure to function: Why the "hemopexin" domain?
10. Multiple modes of activation of latent fibreblast collagenase: Evidence for the role of a Cys73 active-site zinc complex in latency and a "cysteine switch" mechanism for activation
11. Molecular cloning and characterization of human tissue inhibitor of metalloproteinase 4
12. Inhibition of angiogenesis by tissue inhibitor of metalloproteinase-3
13. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinase
14. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis
15. Control of type IV collagenase activity by components of the urokinase-plasmin system: A regulatory mechanism with cell-bound reactants
16. Membrane-type-2 matrix metalloproteinase can initiate the processing of progelatinase A and is regulated by the tissue inhibitors of metalloproteinases
17. Processing of a precursor of 72-kilodalton type IV collagenase/gelatinase A by a recombinant membrane-type I matrix metalloproteinase
18. Identification and characterization of the fifth membrane-type matrix metalloproteinase MT5-MMP
19. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease
20. Identification of soluble type of MT-MMP-3 formed by alternatively spliced mRNA
21. Identification and characterization of human MT5-MMP, a new membrane-bound activator of progelatinase A overexpressed in brain tumors
22. Human MT6-matrix metalloproteinase: Identification, progelatinase A activation, and expression in brain tumors
23. The TIMP2 membrane type I metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A
24. Disruption of angiogenesis by PEX, a noncatalytic metalloproteinase fragment with integrin binding activity
25. Reduced angiogenesis and tumor progression in gelatinase A-deficient mice
26. Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins
27. Pericytes in the microvasculature
28. Inhibition of capillary endothelial cell growth by pericytes and smooth muscle cells
29. A variant derived from rabbit aortic smooth muscle: Phenotype modulation and restoration of smooth muscle characteristics in cells in culture
30. The N-terminal domain of tissue inhibitor of metalloproteinases retains metalloproteinase inhibitory activity
31. The activity of the tissue inhibitor of metalloproteinases is regulated by C-terminal domain interactions: A kinetic analysis of the inhibition of gelatinase A
32. The purification of tissue inhibitor of metalloproteinases-2 from its 72 kDa progelatinase complex. Demonstration of the biochemical similarities of tissue inhibitor of metalloproteinases-2 and tissue inhibitor of metalloproteinases-1
33. Single step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
34. Monitoring mRNA expression by polymerase chain reaction: The "primer-dropping" method
35. MT1-MMP on the cell surface causes focal degradation of gelatin films
36. The role of the C-terminal domain in collagenase and stromelysin specificity
37. Regulation of matrix metalloproteinase expression in human vein and microvascular endothelial cells
38. Plasma membrane-dependent activation of gelatinase A in human vascular endothelial cells
39. Blood vessel formation: What is its molecular basis?
40. Signaling vascular morphogenesis and maintenance
41. MMP-9/gelatinase B is a key regulator of growth plate angiogenesis and apoptosis of hypertrophic chondrocytes
42. Tumor targeting with a selective gelatinase inhibitor
43. Transgenic TIMP-1 inhibits simian virus 40 T antigen-induced hepatocarcinogenesis by impairment of hepatocellular proliferation and tumor angiogenesis
44. VEGF couples hypertrophic cartilage remodeling, ossification and angiogenesis during endochondral bone formation
45. Membrane type I matrix metalloproteinase digests interstitial collagens and other extracellular matrix macromolecules
46. Membrane-type matrix metalloproteinases 1 and 2 exhibit broad-spectrum proteolytic capacities comparable to many matrix metalloproteinases
47. Membrane-type matrix metalloproteinases in human dermal microvascular endothelial cells: Expression and morphogenetic correlation
48. Involvement of PA/plasmin system in the processing of pro-MMP-9 and in the second step of pro-MMP-2 activation
49. Thrombin induces the activation of progelatinase A in vascular endothelial cells
50. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloproteinase docking to invadopodia is required for cell invasion
51. The soluble catalytic domain of membrane type i matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autoproteolytic activation
52. Mechanisms of angiogenesis
53. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice
54. Distinct roles of the receptor tyrosine kinases Tie-1 and Tie-2 in blood vessel formation
55. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis
56. Vascular dysmophogenesis caused by an activating mutation in the receptor tyrosine kinase TIE2
57. Inhibition of endothelial movement by pericytes and smooth muscle cells: Activation of a latent transforming growth factor-beta 1-like molecule by plasmin during coculture